Why Gentrack, Monash IVF, Pro Medicus, and Qube shares are racing higher today

These shares are having a strong start to the week. But why?

| More on:
Excited couple celebrating success while looking at smartphone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Gentrack shares have surged 22% to $8.10 after announcing an 8% rise in revenue and an 18% jump in EBITDA, coupled with reaffirmed ambitious growth targets in its FY2025 results.
  • Monash IVF shares skyrocketed 40% to 85.5 cents following the rejection of an unsolicited takeover proposal from a consortium, as the board deemed the offer undervalued the company.
  • Qube Holdings rose almost 18% to $4.79 on the back of a $5.20 per share takeover bid from Macquarie Group, underscoring confidence in Qube's robust business model and asset quality.

The S&P/ASX 200 Index (ASX: XJO) has returned to form and is on course to start the week with a solid gain. In afternoon trade, the benchmark index is up 1.2% to 8,515.2 points.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing today:

Gentrack Group Ltd (ASX: GTK)

The Gentrack share price is up 22% to $8.10. This follows the release of the airport and utilities software provider's FY 2025 results this morning. Gentrack delivered an 8% increase in revenue to NZ$230.2 million and an 18% jump in EBITDA to NZ$27.8 million for the 12 months. And while no firm guidance was given, management reiterated its mid-term target of more than 15% compound annual revenue growth and an EBITDA margin of 15%–20%.

Monash IVF Group Ltd (ASX: MVF)

The Monash IVF share price is up 40% to 85.5 cents. Investors have been buying this fertility treatment company's shares after it received and rejected "an opportunistic, unsolicited, conditional and non- binding indicative proposal" from a consortium comprising Genesis Capital and Washington H. Soul Pattinson and Co Ltd (ASX: SOL). The indicative cash price offered to shareholders under the proposal was $0.80 per share. However, "the Board has considered the Proposal including with the assistance of its financial and legal advisers and unanimously determined that the Proposal materially undervalues Monash IVF and is not in the best interest of the Company's shareholders as a whole."

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is up 3.5% to $260.59. This morning, the health imaging technology company revealed that it has signed three new contracts with a combined minimum contract value of $29 million. These contracts will be fully cloud-deployed and are planned to be completed within the next six months. Pro Medicus' founder and CEO, Dr Sam Hupert, said: "They comprise a children's hospital, a cancer center, and a physician-owned and run regional healthcare provider. This diversity reinforces our belief that our product is ideally suited to virtually all segments of the market, from smaller groups all the way through to some of the largest IDN's and academic medical centers in the US."

Qube Holdings Ltd (ASX: QUB)

The Qube share price is up almost 18% to $4.79. This has been driven by news that the logistics solutions company has received a takeover offer from Macquarie Group Ltd (ASX: MQG). The Macquarie Asset Management (MAM) business is offering $5.20 per share for Qube. The company's chair, John Bevan, said: "The proposal from Macquarie Asset Management is a reflection of the strength of Qube's business model and our assets, and the quality of our people and culture. We look forward to continuing to engage constructively in the best interests of our shareholders."

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Macquarie Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Gentrack Group, Macquarie Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

rising share price line observed by person
Share Gainers

3 ASX 200 momentum stocks to buy right now

These shares have shown an incredible price rally over the past year.

Read more »

Two men celebrate while another holds his head in his hands, after watching the race.
Share Gainers

Here are the top 10 ASX 200 shares today

Despite the RBA, investors were back to the races this Tuesday.

Read more »

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

These 3 ASX 200 shares have soared over 200% in a year!

And here's what to expect from the high-climbers in 2026.

Read more »

Happy work colleagues give each other a fist pump.
Share Gainers

Why Appen, Imricor, Qoria, and Xero shares are storming higher today

These shares are rising on Tuesday. But why?

Read more »

3 children standing on podiums wearing Olympic medals.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather horrid start to the week's trading today.

Read more »

Three people with gold streamers celebrate good news.
Gold

How is this ASX gold stock rocketing 16% on Monday amid a tanking gold price?

Investors are shrugging off the sinking gold price and piling into this ASX gold stock on Monday. But why?

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why 4DMedical, DroneShield, New Hope, and Zip shares are pushing higher today

These shares are starting the week positively. But why?

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Share Gainers

These were the worst-performing ASX 200 shares in January

Investors were selling off these shares in January. But why?

Read more »